CGON (CG Oncology) Tariff Resilience Score: 8/10 (As of Jul. 04, 2026)


CGON CG Oncology Inc CGON
12 GF Score
Price $70.40
! 5 Warning Signs
View Full Analysis

What is CG Oncology Tariff Resilience Score?

CG Oncology CGON -0.75% 12 Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus rates CGON with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 1,373 Biotechnology companies, CG Oncology ranks better than 98.69% on this metric.

CG Oncology has the Tariff Resilience Score of 8, which implies that the company might have Highly Resilient.

CG Oncology has CG Oncology's focus on biotech and pharmaceuticals, which often have tariff exemptions, reduces vulnerability. Its operations are primarily domestic, and historical tariff changes have had minimal impact on its business.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CG Oncology might have Highly Resilient.

CG Oncology  (NAS:CGON) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CG Oncology Tariff Resilience Score Related Terms

CGON vs COGT, SRRK, LGND: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CG Oncology's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CG Oncology Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CG Oncology's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CG Oncology's Tariff Resilience Score falls into.


CGON
12GF Score
CG Oncology Inc CGON
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 8 mean?
CG Oncology (CGON) has a Tariff Resilience Score of 8 as of Jul. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CG Oncology ranks #18 out of 1373 companies in the Biotechnology industry, placing it in the top 1.3%.
Is CG Oncology's Tariff Resilience Score too high?
CG Oncology's current Tariff Resilience Score is 8. The Biotechnology industry median Tariff Resilience Score is 4.00. CG Oncology's value of 8 is 100% above this industry median. Based on the distribution chart, CG Oncology ranks #18 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CG Oncology has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does CG Oncology's Tariff Resilience Score compare to COGT and SRRK?
According to the Biotechnology industry distribution chart, CG Oncology ranks #18 out of 1373 companies for Tariff Resilience Score. This places CG Oncology in the top 1% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CG Oncology's value of 8 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CG Oncology's current Tariff Resilience Score of 8 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CG Oncology's current Tariff Resilience Score is 8. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CG Oncology stock overvalued right now?
CG Oncology (CGON) has a current Tariff Resilience Score of 8. The current Tariff Resilience Score is 8 and 100% above the Biotechnology industry median of 4.00. CG Oncology's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CG Oncology (CGON), the current Tariff Resilience Score is 8 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CG Oncology Business Description

Address 400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
12GF Score

Get the complete analysis for CGON

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$70.40
Price